Business
VMS Rehab Systems, Inc. offers guidance on BioPharmcor generic drug unit
VMS Rehab Systems, Inc. offers guidance on BioPharmcor generic drug unit.
About this update from Vms Rehab Systems
[{"type":"text","content":"\n\n\n\nVMS Rehab Systems, Inc. offers guidance on BioPharmcor generic drug unit\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVMS Rehab Systems, Inc. offers guidance on BioPharmcor generic drug unit\nPR Newswire\nOTTAWA, Ontario, July 6, 2016\n\n\n\n\n\n\n\nOTTAWA, Ontario, July 6, 2016 /PRNewswire/ -- In advance of European investor meetings for its Dutch based BioPharmcor BV generic drug unit, VMS Rehab Systems, Inc. (www.vmsrehabsystemsinc.com) is providing guidance on forecasted revenues and product development expenditures for the period 2016-2022.\n\nBioPharmcor BV (www.biopharmcor.com) has recently launched a Private Placement of its voting A shares in Central Europe to be followed by a placement of SME Bonds on or before the 4th quarter 2016. It is intended that the Bonds will be floated on the Alternext Brussels Exchange. The Company will be addressing European investors at a series of investor meetings to be held throughout the summer and fall, beginning with a meeting scheduled for Monday, July 11th in Warsaw, Poland.\n\nAccording to Michael S. Wexler, VMS and BioPharmcor Group Board Chairman, \"We anticipate an excellent response from European investors for our BioPharmcor offerings. The selection of generic tadalafil as our initial pipeline product is strategic and will follow as early as possible on the patent expiration of the name brand reference product. Excluding any successful acquisition activity, our preliminary sales forecast through 2022 yields aggregate organic sales of Euro 34 million (US $38 million). We anticipate that year on year sales will grow sharply throughout the decade as generic tadalafil usage continues to rise in all markets worldwide. We must keep in mind that BioPharmcor will be offering its generic tadalafil in several dosages and is a first line treatment for both Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH).\" \n\nAdds Mr. Wexler, \"Equally important to our aggressive market strategy in building out tadalafil sales following regulatory approvals, is our commitment to fort...